Articles tagged with "Biologics & Biosimilars"

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

February 4, 2019 • By Michele B. Kaufman, PharmD, BCGP

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

August 8, 2018 • By Michele B. Kaufman, PharmD, BCGP

The Science Behind Biosimilars

February 27, 2018 • By Arthritis & Rheumatology

Biosimilars: Still Waiting for Promise to Materialize

January 17, 2018 • By Larry Beresford

Sequential Therapy May Reduce Hip Fracture Risk; Plus New Biosimilar Available in Canada

September 27, 2017 • By Michele B. Kaufman, PharmD, BCGP

U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

June 13, 2017 • By Andrew Chung

Nevada Rheumatologists Take on Biologic and Biosimilar Substitution

April 19, 2017 • By Kelly Tyrrell

U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

January 15, 2017 • By Andrew Chung

Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States

January 13, 2017 • By Pfizer

Do RA Patients in Clinical Trials for Biologics Represent the Average?

October 4, 2016 • By Arthritis Care & Research